Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.


Chinese medicine has been practiced in China for thousand years, and it is also used in hundreds of other countries around the world. Following the 2015 Nobel Prize in Physiology or Medicine for the discovery of artemisinin, also known as Qinghaosu, an active component of a Chinese herbal medicine Qinghao, the interest in Chinese medicine research has increased.

The OCMRC is being scaled up from an existing Chinese Herbal Medicine Research Laboratory (CHMRL) established in September 2015 under a research programme agreement between the University of Oxford and Shaanxi Momentum Pharmaceutical Co. Ltd.

The main research currently undertaken is to understand the mechanistic action of a clinically patented Chinese antiarrhythmic multi-herbal medicine Xin Su Ning (XSN).  Dr Yu-ling Ma leads this programme of work in the Department. The research has obtained significant results which clearly identifies XSN as a Class III antiarrhythmic medicine and has led to a joint international patent application between Momentum and University of Oxford.  

Encouraged by our achievements in the last two years, Momentum Pharmaceutical Company is proposing to widen the research of XSN to cover more clinically relevant and translational studies of XSN and eventually make XSN available to patients worldwide.  


1. To provide an experimental framework to study the physiological mechanisms of the clinically effective Chinese herbal medicines used in the most common diseases, such as cardiovascular, metabolic, infectious, digestive system, degenerative and oncological diseases. Initially we will focus on the antiarrhythmic compounds in our Cardiac Science Centre.

2. To provide an experimental pipeline to study the clinical efficacy of compounds extracted from Chinese medicine.

           (i) Training students and researchers 

3. We will establish a training programme for postgraduate students; and establish an exchange programme between University of Oxford and Universities and research institutions in China interested in Chinese medicine research.

           (i) To apply for UK-China joint research grants. The grant will be allocated according to the nature of the research work carried out.

          (ii) Organise research and innovation symposiums.

leadership board

Director: Dr Yu-ling Ma
Honoural Directors: Oxford - Professor David Paterson (Oxford, Basic Science)
China - Mr Bao-An Wang (Pharmaceutical industry)
An Academic TCM expert will be appointed


Professor Kieran Clarke

Professor Anant Parekh

Professor Manuela Zaccolo

Professor Robert Wilkins

Lorna Carter (public member advising on matters relating to ethics)

Professor Clive Ellory (Chair of the Committee)